Octreotide was first approved by the FDA in October 1988 for the treatment of carcinoid tumors and VIPomas. In June 1995, it also received FDA approval for the treatment of acromegaly.

Following this, in November 1998, the FDA approved a long-acting dosage form of octreotide, Sandostatin LAR Depot®, for the treatment of acromegaly and to control the symptoms of carcinoid tumors and VIP adenomas in patients that respond to and tolerate initial treatment with subcutaneous octreotide.

A prescription is required for this medicine.

Please visit the official site of the FDA for further information.

 

Why is this medication prescribed?

Other uses for this medicine

Dosage and using this medicine

What special precautions should I follow?

What should I do if I forget a dose?

What side effects can this medication cause?

What storage conditions are needed for this medicine?

In case of an emergency/overdose